Synthetic Cannabinoids Carry 4-5 Times Higher Psychosis Risk Than Natural Cannabis

Among 85 studies, synthetic cannabinoids showed consistently higher psychosis risk than traditional cannabis (OR 4.4-5.2 for synthetic cannabinoids vs cannabis). Distinct clinical profiles emerged: synthetic cannabinoid "spiceophrenia" featured visual hallucinations (73-84%), agitation (79-91%), and anxiety (62-76%). Key vulnerability factors included pre-existing psychiatric conditions, adolescent exposure, and polysubstance use. Different substance classes showed different neurobiological mechanisms.

Comprehensive systematic review following PRISMA guidelines across five databases (January 2005-December 2022). Quality assessed using Newcastle-Ottawa Scale and JBI checklist. Of 684 records, 85 met inclusion: case reports (38), retrospective cohorts (25), cross-sectional (10), case-control (7), experimental (3), prospective cohort (2).

While natural cannabis psychosis risk receives significant attention, synthetic cannabinoids pose a dramatically higher risk that is less well recognized. The identification of "spiceophrenia" as a distinct clinical entity with characteristic visual hallucinations and extreme agitation could improve emergency recognition and treatment.

Synthetic cannabinoids continue to evolve to evade regulation, and their psychosis risk is dramatically higher than natural cannabis. The finding that they produce a distinct clinical syndrome ("spiceophrenia") argues for separate clinical protocols and public health messaging rather than lumping them with cannabis.

Predominantly case reports and retrospective studies. Publication bias toward severe outcomes. Rapidly evolving synthetic cannabinoid landscape means newer compounds may differ. Polysubstance use complicates attribution. Heterogeneous study designs limit direct comparisons.